[News] Government shutdown and Medicare changes impact cancer care in the USA

2nd Dec, 2025

Oncology

The Lancet

The effects of Medicare funding cuts and the longest ever shutdown of the US Federal Government have slowed momentum to a standstill in cancer prevention, screening, and treatment, warned the Association of American Cancer Institutes (AACI), which represents more than 100 academic and freestanding cancer centres in the USA and Canada.

Published By: The Lancet

Oncology

31st Dec, 2025

Journal of the American Medical Association

A Scalable Model to Improve Cancer Care for Older Adults

Oncology

15th Jan, 2026

The Lancet

[Clinical Picture] High-output cardiac failure from a synovial sarcoma mimicking arteriovenous fistula

Oncology

15th Jan, 2026

The Lancet

[Review] Development of a core outcome set for adolescents and young adults with cancer

Oncology

15th Jan, 2026

The Lancet

[Policy Review] International consensus recommendations and alignment of terminology for the histopathological diagnosis of extranodal extension in head and neck squamous cell carcinoma: an HN-CLEAR initiative

Oncology

15th Jan, 2026

The Lancet

[Policy Review] A comprehensive framework for glioma surgery by the PIONEER Consortium and RANO resect group, part 2: perioperative recommendations for neurological, language, functional, and quality-of-life assessment

Oncology

15th Jan, 2026

The Lancet

[Policy Review] A comprehensive framework for glioma surgery by the PIONEER Consortium and RANO resect group, part 1: intraoperative recommendations for mapping, monitoring, and decision making

Oncology

15th Jan, 2026

The Lancet

[Articles] Tiragolumab plus atezolizumab and chemotherapy as first-line treatment for patients with unresectable oesophageal squamous cell carcinoma (SKYSCRAPER-08): a randomised, double-blind, placebo-controlled, phase 3 trial

[News] Government shutdown and Medicare changes impact cancer care in the USA

Related Articles

A Scalable Model to Improve Cancer Care for Older Adults

[Clinical Picture] High-output cardiac failure from a synovial sarcoma mimicking arteriovenous fistula

[Review] Development of a core outcome set for adolescents and young adults with cancer

[Policy Review] International consensus recommendations and alignment of terminology for the histopathological diagnosis of extranodal extension in head and neck squamous cell carcinoma: an HN-CLEAR initiative

[Policy Review] A comprehensive framework for glioma surgery by the PIONEER Consortium and RANO resect group, part 2: perioperative recommendations for neurological, language, functional, and quality-of-life assessment

[Policy Review] A comprehensive framework for glioma surgery by the PIONEER Consortium and RANO resect group, part 1: intraoperative recommendations for mapping, monitoring, and decision making

[Articles] Tiragolumab plus atezolizumab and chemotherapy as first-line treatment for patients with unresectable oesophageal squamous cell carcinoma (SKYSCRAPER-08): a randomised, double-blind, placebo-controlled, phase 3 trial

[News] Government shutdown and Medicare changes impact cancer care in the USA

Related Articles

A Scalable Model to Improve Cancer Care for Older Adults

[Clinical Picture] High-output cardiac failure from a synovial sarcoma mimicking arteriovenous fistula

[Review] Development of a core outcome set for adolescents and young adults with cancer

[Policy Review] International consensus recommendations and alignment of terminology for the histopathological diagnosis of extranodal extension in head and neck squamous cell carcinoma: an HN-CLEAR initiative

[Policy Review] A comprehensive framework for glioma surgery by the PIONEER Consortium and RANO resect group, part 2: perioperative recommendations for neurological, language, functional, and quality-of-life assessment

[Policy Review] A comprehensive framework for glioma surgery by the PIONEER Consortium and RANO resect group, part 1: intraoperative recommendations for mapping, monitoring, and decision making

[Articles] Tiragolumab plus atezolizumab and chemotherapy as first-line treatment for patients with unresectable oesophageal squamous cell carcinoma (SKYSCRAPER-08): a randomised, double-blind, placebo-controlled, phase 3 trial